Latest in Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes

Find out more

Survey: 65% of pharma marketers distrust AI for regulatory submissions amid fears about hallucinations and traceability

A new survey reveals deep scepticism toward AI-generated regulatory materials, with pharma teams citing hallucinations, poor auditability and lack of transparency as major risks
See more

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone

Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response

The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models

Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research

The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases

BioMed X announces neuroscience research partnership with AbbVie

The new project, taking place at BioMed X's institute in New Haven, will aim to uncover the mechanisms of anhedonia and identify novel therapeutic targets

Bracco, Limula and the University of Fribourg partner to advance next-gen cell and gene therapy manufacturing in Switzerland

A new Swiss industry–academia collaboration aims to improve CAR-T and cell therapy production by combining Bracco’s microbubble technology with Limula’s automated processing platform

Novo Nordisk’s oral semaglutide fails to slow Alzheimer’s progression in global Phase III trials

The studies showed no statistically significant benefit on disease progression despite biomarker improvements, leading to a sharp drop in the company's share price

Bayer expands global partnership with TetraScience to accelerate AI-driven scientific data management

Bayer is scaling TetraScience’s Scientific Data Foundry across its pharma and crop science R&D teams to unify and harmonise laboratory and CRO data. The expansion aims to streamline regulatory workflows and enable faster, AI-ready analysis across global programmes

Aseptic spray drying: Transforming biotherapeutics for a new era

With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications

Latest posts in Research & Development

ChristianaCare launches organoid core to personalise cancer treatment in Delaware

The new facility at the Helen F. Graham Cancer Center grows patient-derived mini-tumours to test therapies, helping doctors tailor cancer treatments and accelerate translational research in a community setting

UK Invests £9.9m to turn recycled nuclear material into lead-212 cancer therapies

A new UK-wide programme will use recycled nuclear fuel to create sustainable lead-212 targeted alpha therapies, aiming to deliver next-generation precision cancer treatments for hard-to-treat tumours

OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer

The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer

American Cancer Society expands ACS ACTS programme to boost equity in cancer clinical trials nationwide

Leveraging trained specialists and AI-powered trial matching, the ACS ACTS programme helps patients, caregivers and providers navigate clinical trial options while addressing barriers to participation

Akeso wins NMPA approval to trial first China-developed bispecific Alzheimer’s antibody

China’s NMPA has cleared Akeso to begin clinical trials of AK152, a bispecific antibody designed to improve brain penetration and enhance Aβ plaque clearance

Novartis’ next-generation malaria treatment GanLum hits Phase III target with 97% cure rate

Phase III trial of KLU156 (ganaplacide/lumefantrine) shows high efficacy against drug-resistant malaria, with potential to block transmission and transform treatment across Africa

BetaGlue Therapeutics gains MHRA approval for pancreatic cancer trial

YntraDose, the innovative radiotherapy treatment for unresectable locally advanced pancreatic cancer, has been granted an early feasibility clinical investigation and will assess safety and performance in patients

Scottish immunology CRO RoukenBio celebrates 10 years of growth

Formerly known as Antibody Analytics, the contract research organisation has grown from three employees to over 100 and enjoyed successes such as the launch of its first proprietary technology, IndEx-2 and multi-million pound investments

DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children

The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year

Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling

The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry

Patient dies in CRISPR gene therapy trial

The FDA has now placed Intellia Therapeutics' Phase III CRISPR trials on hold over raised liver enzymes

Sponsor content

Redefining QP training for today’s professionals

How NSF is making specialist learning more flexible and accessible

NSF’s QP training program combines technical skill with personalised guidance

A mentoring-led approach supporting delegates through every stage of the QP journey

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples

Cut Argon use and costs with Shimadzu’s ICPMS-2040/2050

New Mini-Torch System offers precision analysis with 40% less Argon

Driving ADC innovation with complex chemistry solutions

Abzena’s tailored chemistry expertise enables scalable, high-quality bioconjugate development from discovery to GMP production

ProImmune Ltd introduces ProVE SL Self-Loading MHC Class I Monomers to improve T cell research flexibility

ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE® SL Self-Loading MHC Class I Monomers. The novel...

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates

Featured companies

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life... The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services to the pharmaceutical and biotech... At Biotech Fluidics, our aim is to help you make your analytical work more effective and reliable. Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small-molecule and peptide drug...
See more